Pharmaceutics 2021, 13, 927
18 of 19
47. Tjølsen, A.; Berge, O.G.; Hunskaar, S.; Rosland, J.H.; Hole, K. The formalin test: An evaluation of the method. Pain 1992, 51, 5–17.
48. Jourdan, D.; Ardid, D.; Bardin, L.; Neuzeret, D.; Lanphouthacoul, L.; Eschalier, A. A new automated method of pain scoring in
the formalin test in rats. Pain 1997, 71, 265–270. [CrossRef]
49. Hill, R.; Disney, A.; Conibear, A.; Sutcliffe, K.; Dewey, W.; Husbands, S.; Bailey, C.; Kelly, E.; Henderson, G. The novel µ-opioid
receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br. J. Pharmacol. 2018, 175, 2653–2661.
50. Wang, X.; Traub, R.J.; Murphy, A.Z. Persistent pain model reveals sex difference in morphine potency. Am. J. Physiol. Integr. Comp.
Physiol. 2006, 291, R300–R306. [CrossRef]
51. Grant, G.J.; Vermeulen, K.; Zakowski, M.I.; Stenner, M.; Turndorf, H.; Langerman, L. Prolonged analgesia and decreased toxicity
with liposomal morphine in a mouse model. Anesth. Analg. 1994, 79, 706–709. [CrossRef]
52. Dahan, A.; Van Der Schrier, R.; Smith, T.; Aarts, L.; Van Velzen, M.; Niesters, M. Averting opioid-induced respiratory depression
without affecting analgesia. Anesthesiology 2018, 128, 1027–1037. [CrossRef]
53. Hill, R.; Lyndon, A.; Withey, S.; Roberts, J.; Kershaw, Y.; Maclachlan, J.; Lingford-Hughes, A.; Kelly, E.; Bailey, C.; Hickman, M.;
et al. Ethanol reversal of tolerance to the respiratory depressant effects of morphine. Neuropsychopharmacology 2016, 41, 762–773.
54. Hill, R.; Santhakumar, R.; Dewey, W.; Kelly, E.; Henderson, G. Fentanyl depression of respiration: Comparison with heroin and
morphine. Br. J. Pharmacol. 2020, 177, 254–266. [CrossRef]
55. Kosten, T.R.; George, T.P. The neurobiology of opioid dependence: Implications for treatment. Sci. Pract. Perspect. 2002, 1, 13–20.
56. Liu, L.; Coller, J.K.; Watkins, L.R.; Somogyi, A.A.; Hutchinson, M.R. Naloxone-precipitated morphine withdrawal behavior and
brain IL-1β expression: Comparison of different mouse strains. Brain. Behav. Immun. 2011, 25, 1223–1232. [CrossRef]
57. Suzuki, T.; Yoshii, T.; Yanaura, S. Induction of Physical Dependence on Morphine in Mice by the Drug-Admixed Food Method.
Jpn. J. Pharmacol. 1984, 34, 319–325. [CrossRef]
58. Dumas, E.O.; Pollack, G.M. Opioid tolerance development: A pharmacokinetic/pharmacodynamic perspective. AAPS J. 2008, 10,
59. Yuan, B.Y.; Liu, W.Z.; Wang, X.F.; Zhang, Y.Z.; Yang, D.J.; Wang, C.L. Endomorphin-1 analogs with oligoarginine-conjugation at
C-terminus produce potent antinociception with reduced opioid tolerance in paw withdrawal test. Peptides 2018, 106, 96–101.
60. Le Naour, M.; Akgün, E.; Yekkirala, A.; Lunzer, M.M.; Powers, M.D.; Kalyuzhny, A.E.; Portoghese, P.S. Bivalent ligands that target
µ opioid (MOP) and cannabinoid1 (CB 1) receptors are potent analgesics devoid of tolerance. J. Med. Chem. 2013, 56, 5505–5513.
61. Mansouri, M.T.; Khodayar, M.J.; Tabatabaee, A.; Ghorbanzadeh, B.; Naghizadeh, B. Modulation of morphine antinociceptive
tolerance and physical dependence by co-administration of simvastatin. Pharmacol. Biochem. Behav. 2015, 137, 38–43. [CrossRef]
62. Ren, X.; Noda, Y.; Mamiya, T.; Nagai, T.; Nabeshima, T. A neuroactive steroid, dehydroepiandrosterone sulfate, prevents the
development of morphine dependence and tolerance via c-fos expression linked to the extracellular signal-regulated protein
kinase. Behav. Brain Res. 2004, 152, 243–250. [CrossRef]
63. Yamazaki, M.; Suzuki, T.; Narita, M.; Lipkowski, A.W. The opioid peptide analogue biphalin induces less physical dependence
than morphine. Life Sci. 2001, 69, 1023–1028. [CrossRef]
64. Sitbon, P.; Van Elstraete, A.; Hamdi, L.; Juarez-Perez, V.; Mazoit, J.X.; Benhamou, D.; Rougeot, C. STR-324, a Stable Analog
of Opiorphin, Causes Analgesia in Postoperative Pain by Activating Endogenous Opioid Receptor-dependent Pathways.
Anesthesiology 2016, 125, 1017–1029. [CrossRef]
65. Roques, B.P.; Noble, F.; Daugé, V.; Fournié-Zaluski, M.C.; Beaumont, A. Neutral endopeptidase 24.11: Structure, inhibition, and
experimental and clinical pharmacology. Pharmacol. Rev. 1993, 45, 87–146.
66. Raffa, R.B.; Pergolizzi, J.V.; Taylor, R.; Ossipov, M.H. Indirect-acting strategy of opioid action instead of direct receptor activation:
Dual-acting enkephalinase inhibitors (DENKIs). J. Clin. Pharm. Ther. 2018, 43, 443–449. [CrossRef]
67. Popik, P.; Kamysz, E.; Kreczko, J.; Wróbel, M. Human opiorphin: The lack of physiological dependence, tolerance to antinocicep-
tive effects and abuse liability in laboratory mice. Behav. Brain Res. 2010, 213, 88–93. [CrossRef]
68. Mello, N.K.; Mendelson, J.H. Self-administration of an enkephalin analog by rhesus monkey. Pharmacol. Biochem. Behav. 1978
.
69. Lowery, J.J.; Raymond, T.J.; Giuvelis, D.; Bidlack, J.M.; Polt, R.; Bilsky, E.J. In vivo characterization of MMP-2200, a mixed δ/µ
opioid agonist, in mice. J. Pharmacol. Exp. Ther. 2011, 336, 767–778. [CrossRef]
70. Hökfelt, T.; Bartfai, T.; Bloom, F. Neuropeptides: Opportunities for drug discovery. Lancet Neurol. 2003, 2, 463–472. [CrossRef]
71. Godfrey, L.; Iannitelli, A.; Garrett, N.L.; Moger, J.; Imbert, I.; King, T.; Porreca, F.; Soundararajan, R.; Lalatsa, A.; Schätzlein, A.G.;
et al. Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. J. Control. Release 2018, 270,
72. Horan, P.J.; Mattia, A.; Bilsky, E.J.; Weber, S.; Davis, T.P.; Yamamura, H.I.; Malatynska, E.; Appleyard, S.M.; Slaninova, J.; Misicka,
A.; et al. Antinociceptive profile of biphalin, a dimeric enkephalin analog. J. Pharmacol. Exp. Ther. 1993, 265, 1446–1454.